CompanyGraphAt a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $1.8B, above the global median of $520.53M
- PositionCurrent ratio is 0.94×, lower than 95% of its Biotechnology peers (median 5.64×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.92%Above 5Y avg (2.20%)
Annual Rate
KRW 300.00Paid annual
Payout Ratio
0.0%Sustainable
Payback Period
33.2 yr
Last Ex-Dividend
Mar 30, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
467.13BKRW336.60M · vs all stocks (USD)
Revenue (TTM)
2.49TKRW1.80B · vs all stocks (USD)
Profit Margin
-3.60%vs Biotechnology peers
Beta
0.5650xvs all stocks
52-Week Change
-31.65%vs all stocks
Market Capitalization
467.13BKRW336.60M · vs all stocks (USD)
Enterprise Value
2.83TKRW2.04B · vs all stocks (USD)
Price to Sales (TTM)
0.1829xvs Biotechnology peers
Price to Book (MRQ)
0.2687xvs Biotechnology peers
Enterprise to Revenue
1.14xvs Biotechnology peers
Enterprise to EBITDA
18.71xvs Biotechnology peers
Gross Margin
28.96%vs Biotechnology peers
Profit Margin
-3.60%vs Biotechnology peers
Operating Margin
0.57%vs Biotechnology peers
Return on Assets (TTM)
0.66%vs Biotechnology peers
Return on Equity (TTM)
-5.06%vs Biotechnology peers
Revenue (TTM)
2.49TKRW1.80B · vs all stocks (USD)
Revenue per Share (TTM)
55.51KKRWUpdated Aug 20, 2026Quarterly Revenue Growth
8.10%vs Biotechnology peers
Gross Profit (TTM)
696.77BKRW502.07M · vs all stocks (USD)
EBITDA (TTM)
197.27BKRW142.14M · vs all stocks (USD)
Net Income (TTM)
-88.86BKRW-64.03M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
8.13%vs Biotechnology peers
Operating Cash Flow (TTM)
123.65BKRW89.10M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-25.06BKRW-18.06M · vs all stocks (USD)
Trailing Annual Dividend Rate
300.00KRWUpdated Aug 20, 2026Trailing Annual Dividend Yield
2.92%vs all stocks
5-Year Average Dividend Yield
2.20%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
862.84BKRWFY2025 · Dec 31, 2025Revenue
2.45TKRWFY2025 · Dec 31, 2025Cost of Goods Sold
1.77TKRWFY2025 · Dec 31, 2025Gross Profit
682.74BKRWFY2025 · Dec 31, 2025Operating Income
36.46BKRW26.27M · vs all stocks (USD)
Pre-tax Income
-53.44BKRWFY2025 · Dec 31, 2025Income Tax Expense
-11.62BKRWFY2025 · Dec 31, 2025Net Income
-41.82BKRWFY2025 · Dec 31, 2025EBIT
18.56BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
225.77BKRWFY2025 · Dec 31, 2025Research & Development
157.26BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
228.44BKRWFY2025 · Dec 31, 2025Other Operating Expenses
9.62BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
5.54BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
72.00BKRWFY2025 · Dec 31, 2025EPS (Basic)
-1.53KKRWFY2025 · Dec 31, 2025EPS (Diluted)
-1.53KKRWFY2025 · Dec 31, 2025Basic Shares Outstanding
45.40MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
45.40MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-41.82BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
-27.69BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-16.37BKRWFY2025 · Dec 31, 2025Free Cash Flow
-123.67BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
79.66BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-41.82BKRWFY2025 · Dec 31, 2025Other Non-cash Items
67.18BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-38.12BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.62BKRWFY2025 · Dec 31, 2025Capital Expenditures
-107.30BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-34.51BKRWFY2025 · Dec 31, 2025Net Acquisitions
-134.27BKRWFY2025 · Dec 31, 2025Purchase of Investments
-92.14BKRWFY2025 · Dec 31, 2025Sale of Investments
113.75BKRWFY2025 · Dec 31, 2025Other Investing Activity
10.00KRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-219.96BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
408.70BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-1.76TKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-43.20BKRWFY2025 · Dec 31, 2025Common Dividends Paid
-33.21BKRWFY2025 · Dec 31, 2025Other Financing Charges
-96.28BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.53TKRWFY2025 · Dec 31, 2025Shares Outstanding
44.97MSharesUpdated Aug 20, 2026Float Shares
24.39MSharesUpdated Aug 20, 2026% Held by Insiders
49.83%vs all stocks
% Held by Institutions
11.68%vs all stocks
Total Cash (MRQ)
101.93BKRW73.45M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.27KKRWUpdated Aug 20, 2026Total Debt (MRQ)
1.62TKRW1.17B · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.9437xvs Biotechnology peers
Current Ratio (MRQ)
0.9420xvs Biotechnology peers
Book Value per Share (MRQ)
38.26KKRWUpdated Aug 20, 2026Total Assets
4.07TKRW2.93B · vs all stocks (USD)
Total Current Assets
1.55TKRWFY2025 · Dec 31, 2025Total Liabilities
2.31TKRWFY2025 · Dec 31, 2025Total Non-current Assets
2.52TKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
697.40BKRWFY2025 · Dec 31, 2025Total Current Liabilities
1.61TKRWFY2025 · Dec 31, 2025Cash
79.66BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
79.66BKRWFY2025 · Dec 31, 2025Other Short-term Investments
19.63BKRWFY2025 · Dec 31, 2025Accounts Receivable
477.92BKRWFY2025 · Dec 31, 2025Inventory
909.80BKRWFY2025 · Dec 31, 2025Accounts Payable
222.52BKRWFY2025 · Dec 31, 2025Short-term Debt
909.46BKRWFY2025 · Dec 31, 2025Other Current Liabilities
48.74BKRWFY2025 · Dec 31, 2025Long-term Debt
583.83BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
20.98BKRWFY2025 · Dec 31, 2025Common Stock (Book)
25.32BKRWFY2025 · Dec 31, 2025Retained Earnings
806.79BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
1.76TKRW1.27B · vs all stocks (USD)
Treasury Stock
18.15BKRWFY2025 · Dec 31, 202552-Week Low
8.63KKRWUpdated Aug 20, 202652-Week High
18.01KKRWUpdated Aug 20, 202652-Week Change
-31.65%vs all stocks
Beta
0.5650xvs all stocks
50-Day MA
10.13KKRWUpdated Aug 20, 2026200-Day MA
13.87KKRWUpdated Aug 20, 2026Avg 10-Day Volume
71.13KSharesUpdated Aug 20, 2026Avg 30-Day Volume
77.58KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-1.53KKRWUpdated Aug 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.94×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.94Industry median: 5.64Industry P5: 1.06Peers compared: 261
Debt-to-equity is 0.94×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 0.94Industry median: 0.09Industry P95: 0.88Peers compared: 261
Price-to-book is 0.27×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.27Industry median: 2.97Industry P5: 1.03Peers compared: 261
Financial Health
Altman Z-Score 1: distress zoneCritical
Altman Z-Score: 1.00
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $1.8B, above the global median of $520.53MNotable
Revenue (USD): 1,795,397,407.316Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Organogenesis Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jilin Jian Yisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
CapsoVision, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanxi C&Y Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Enwei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Perspective Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Inhibikase Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Palisade Bio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xinguang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vanda Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Avery Dennison Corporation
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Mastercard Incorporated
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Financial Partners Group Co., Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated